Stocks
Intelligent OutlookAMGN-
Intelligent Outlook
AMGN-
Prev Close-
50D MA-
200D MA-
52W High-
Live Price
AMGN 24H Rolling
0.000.00%0.00
Rolling: Last 24h | 5m
AMGN
Asset Information
Company Profile
Company:AMGN
Sector:Biotechnology
Industry:Biotechnology
Country:US
Employees:28,000
IPO Date:1983-06-17
Website:www.amgen.com/
Technicals & Growth
Market Cap:$172.20B
Shares O/S:538,361,851
52W High:$335.88
52W Low:$253.30
50D MA:$288.09
200D MA:$291.56
Financial Ratios
P/E Ratio:24.72
EPS:$12.94
Profit Margin:20.98%
ROE (TTM):89.06%
ROA (TTM):8.51%
Div. Per Share:$9.39
AMGN
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Loading chart library...
Financial Data (Macrotrends)
Historical Data
Loading...